We are excited to announce that we have received our first purchase order for 20,000 units of its VISITECT® CD4 Advanced Disease test from our partner company in Zimbabwe. Whilst the VISITECT® CD4 Advanced Disease test is currently undergoing review by the UNITAID-funded Expert Review Panel for Diagnostics (ERPD), the order from Zimbabwe is not contingent upon conclusion of the ERPD process as this order will supply into B2B marketing channels, rather than NGOs.

Read the full announcement here